These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 7994780)

  • 1. Superficial bladder cancer: state of the art.
    Bono AV
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S101-9. PubMed ID: 7994780
    [No Abstract]   [Full Text] [Related]  

  • 2. [Indications for topical therapy in superficial bladder cancer].
    Krege S
    Urologe A; 1992 Jul; 31(4):201-2. PubMed ID: 1514197
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy.
    Sekine H; Fukui I; Yamada T; Yamada T; Kojima S; Ohshima H
    J Urol; 1996 Jan; 155(1):94-8; discussion 98-9. PubMed ID: 7490908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical management of superficial bladder cancer (stages Ta/T1/CIS).
    Smith JA
    Semin Surg Oncol; 1997; 13(5):328-34. PubMed ID: 9259088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
    Rintala E; Jauhiainen K; Alfthan O
    Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270
    [No Abstract]   [Full Text] [Related]  

  • 7. [Quantitative immunocytology as a marker for indications and follow-up of recurrence prevention of superficial urinary bladder cancers].
    Schneider AW; Huland E; Huland H
    Urologe A; 1989 Sep; 28(5):289-91. PubMed ID: 2815438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer.
    Burk K; Kurth KH; Newling D
    Prog Clin Biol Res; 1989; 303():423-34. PubMed ID: 2780657
    [No Abstract]   [Full Text] [Related]  

  • 10. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy.
    Duque JL; Loughlin KR
    Urol Clin North Am; 2000 Feb; 27(1):125-35, x. PubMed ID: 10696251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Which superficial bladder tumors should be treated directly with intravesical chemotherapy?].
    De Jong Z; Pontonnier F; Plante P; Mansat A; Centa F
    Presse Med; 1989 Sep; 18(29):1437-8. PubMed ID: 2529531
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer.
    Jauhiainen K; Rintala E; Kaasinen E; Ruutu M; Alfthan O
    Arch Esp Urol; 1990; 43 Suppl 2():159-64. PubMed ID: 2129004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
    van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W
    Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response.
    Fukui I; Kihara K; Sekine H; Tachibana Y; Kawai T; Ishiwata D; Oshima H
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S37-40. PubMed ID: 1394814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical BCG therapy in patients with superficial bladder tumors.
    Steg A; Belas M; Leleu C; Boccon-Gibod L
    Prog Clin Biol Res; 1989; 310():153-60. PubMed ID: 2771990
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I/II study of intravesical epirubicin in patients with carcinoma in situ of the bladder.
    Kurth KH; Mross K; ten Kate F; Weissglas G; Carpentier PJ; Krueger CG; Blom J; Groen JM; van Caubergh RD; van Aubel O
    Prog Clin Biol Res; 1990; 350():41-59. PubMed ID: 2385609
    [No Abstract]   [Full Text] [Related]  

  • 18. Instillation therapy in superficial urinary bladder cancer. Finnbladder Group.
    Jauhiainen KE; Alfthan OS
    Scand J Urol Nephrol Suppl; 1991; 138():179-85. PubMed ID: 1785001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation.
    Pieras E; Palou J; Salvador J; Rosales A; Marcuello E; Villavicencio H
    Eur Urol; 2003 Aug; 44(2):222-5; discussoion 225. PubMed ID: 12875942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of advanced bladder cancer.
    Sternberg CN
    Ann Oncol; 1995 Feb; 6(2):113-26. PubMed ID: 7786818
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.